About this trial
The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or above
Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT)
Informed consent
Disqualifiers
Patients lacking capacity to give informed consent.
Trial population
All patients diagnosed with one or more primary or secondary liver malignancy who are candidates for thermal liver ablation as discussed in a multidisciplinary tumour board.
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Efficacy as assessed by local recurrence
Efficacy as assessed by time-to-recurrence
Efficacy as assessed by disease-free-survival
Efficacy as assessed by overall survival
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Leiden University Medical Center
Lead sponsor
Philips Healthcare
Collaborator
European Commission
Collaborator